Gulf International Bank UK Ltd Has $27.04 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Gulf International Bank UK Ltd cut its holdings in Johnson & Johnson (NYSE:JNJ) by 1.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 186,962 shares of the company’s stock after selling 2,096 shares during the quarter. Johnson & Johnson makes up about 0.7% of Gulf International Bank UK Ltd’s holdings, making the stock its 22nd largest holding. Gulf International Bank UK Ltd’s holdings in Johnson & Johnson were worth $27,038,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of JNJ. IFS Advisors LLC boosted its position in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares during the last quarter. Bay Harbor Wealth Management LLC acquired a new position in Johnson & Johnson during the 4th quarter worth approximately $32,000. RPg Family Wealth Advisory LLC acquired a new position in Johnson & Johnson during the 3rd quarter worth approximately $35,000. Activest Wealth Management acquired a new position in Johnson & Johnson during the 3rd quarter worth approximately $40,000. Finally, Fiduciary Advisors Inc. acquired a new position in Johnson & Johnson during the 4th quarter worth approximately $43,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on JNJ. Wolfe Research began coverage on Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective on the stock. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Leerink Partners dropped their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Citigroup dropped their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Finally, Raymond James dropped their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $170.67.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.9 %

JNJ stock opened at $165.23 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a market capitalization of $397.81 billion, a price-to-earnings ratio of 24.85, a PEG ratio of 2.56 and a beta of 0.52. The business’s fifty day moving average price is $150.90 and its two-hundred day moving average price is $156.04. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the business earned $2.29 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.00%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.